Protara Therapeutics (TARA) Cash from Investing Activities (2013 - 2026)

Protara Therapeutics' Cash from Investing Activities history runs 14 years deep, the most recent figure standing at -$14.7 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 74.77% year-over-year to -$14.7 million; the TTM figure through Mar 2026 stood at -$95.9 million (down 53.87% YoY), while the FY2025 annual figure was -$139.5 million, down 828.22% from the prior year.
• Cash from Investing Activities was -$14.7 million for Q1 2026 at Protara Therapeutics, up from -$26.9 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $23.1 million in Q1 2024 to a low of -$58.4 million in Q1 2025.
• Historically, Cash from Investing Activities has averaged -$3.9 million across 5 years, with a median of $2.9 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Cash from Investing Activities surged 17701.87% in 2022, then sank 1720.48% in 2025.
• A 5-year view of Cash from Investing Activities shows it stood at -$18.3 million in 2022, then jumped by 179.14% to $14.5 million in 2023, then surged by 54.98% to $22.5 million in 2024, then sank by 219.59% to -$26.9 million in 2025, then jumped by 45.29% to -$14.7 million in 2026.
• The last three Cash from Investing Activities figures came in at -$14.7 million (Q1 2026), -$26.9 million (Q4 2025), and -$6.5 million (Q3 2025), per Business Quant data.